Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Institutional Ownership: 15.57% (As of Sep. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688513 Chengdu Easton Biopharmaceuticals Co Ltd SHSE:688513
86 GF Score
Price ¥44.98
GF Value ¥45.95
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Chengdu Easton Biopharmaceuticals Co Institutional Ownership?

Chengdu Easton Biopharmaceuticals Co SHSE:688513 +2.02% 86 Institutional Ownership is 15.57% as of Sep. 03, 2026. GuruFocus rates SHSE:688513 with a GF Score™ of 86/100 and a GF Value™ of ¥45.95 (Fairly Valued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Chengdu Easton Biopharmaceuticals Co's institutional ownership is 15.57%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Chengdu Easton Biopharmaceuticals Co's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Chengdu Easton Biopharmaceuticals Co's Float Percentage Of Total Shares Outstanding is 0.00%.

Chengdu Easton Biopharmaceuticals Co Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Chengdu Easton Biopharmaceuticals Co's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chengdu Easton Biopharmaceuticals Co Institutional Ownership Chart

Chengdu Easton Biopharmaceuticals Co Historical Data

The historical data trend for Chengdu Easton Biopharmaceuticals Co can be seen below:

2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31 2026-08-31
Institutional Ownership 11.29 17.18 17.16 17.16 17.22 17.21 17.24 17.11 17.11 15.57
SHSE:688513
86GF Score
Chengdu Easton Biopharmaceuticals Co Ltd SHSE:688513
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chengdu Easton Biopharmaceuticals Co Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 15.57% mean?
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) has a Institutional Ownership of 15.57% as of Sep. 03, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors.
Is Chengdu Easton Biopharmaceuticals Co's Institutional Ownership too high?
Chengdu Easton Biopharmaceuticals Co's current Institutional Ownership is 15.57%. Overall, Chengdu Easton Biopharmaceuticals Co has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Easton Biopharmaceuticals Co's Institutional Ownership compare to VRTX and REGN?
Chengdu Easton Biopharmaceuticals Co's Institutional Ownership of 15.57% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. Chengdu Easton Biopharmaceuticals Co's current Institutional Ownership is 15.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Easton Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co (SHSE:688513) is currently considered Fairly Valued. The stock's GF Value™ is ¥45.95, compared to a current price of ¥44.98 — trading 2.1% below its estimated fair value. The current Institutional Ownership is 15.57%. Chengdu Easton Biopharmaceuticals Co's overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Chengdu Easton Biopharmaceuticals Co (SHSE:688513), the current Institutional Ownership is 15.57% as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Overvalued in 2026?

Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co stock appears to be undervalued. The current stock price of ¥44.98 is trading 2.1% below its estimated GF Value™ of ¥45.95. GuruFocus considers Chengdu Easton Biopharmaceuticals Co to be Fairly Valued.

Key valuation signals for SHSE:688513:

  • Institutional Ownership: 15.57%
  • GF Value™: ¥45.95 vs. price of ¥44.98 (2.1% below fair value)
  • GF Score™: 86/100 with 4 warning signs

No single metric tells the full story. See the SHSE:688513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chengdu Easton Biopharmaceuticals Co Business Description

Address No. 8, Xiyuan Avenue, Chengdu High-tech Zone, Sichuan Province, Chengdu, CHN, 611731
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.
86GF Score

Get the complete analysis for SHSE:688513

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥44.98
Price
¥45.95
GF Value